On Squawk Box this morning, CEOs from various industries aired their insights on the economy, energy prices, real estate and politics.
So, yesterday I posited a theory that the weak American economy might be hurting sales growth of erectile dysfunction drugs. I wondered whether men might be cutting their pills in half and/or not filling their expensive prescriptions if they're having to tighten their belts.
Stocks declined as oil resumed its ascent and investors braced for the next batch of corporate earnings. A drop in home sales and a jump in jobless claims above the key 400,000 mark added some pressure.
Bristol-Myers Squibb on Thursday posted quarterly earnings that beat forecasts, helped by higher sales of blood clot preventer Plavix and schizophrenia treatment Abilify, and the company announced an additional $1 billion in planned cost cuts.
Eli Lilly said on Thursday that second-quarter earnings rose on higher sales of its prescription drugs and sharply lower taxes, but the company cut its 2008 profit forecast due to special charges.
Oil's move to a six-week low has been cheering the stock market, but the question is for how long?
Following are the “Fast & Furious” trades - hot ways to play tomorrow's market moving events.
On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."
Pfizer Wednesday said quarterly earnings more than doubled on higher sales of its prescription drugs and lower expenses, but its Chantix quit-smoking drug lost more than a third of its U.S. sales amid safety concerns.
More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.
One day does not a full-fledged sector rotation make, but yesterday the big pharma stocks put on a show and in the early going today the curtain hasn't fallen. Pfizer even broke above 18 bucks!
The debate about whether stocks are finding a floor is gaining momentum, but traders agree it's the earnings season that will help decide the details.
New evidence of the power of the multi-billion dollar impotence drugs. A study just out in the peer-reviewed "British Medical Journal" says that the elderly are having sex more often, possibly due to the popular pills for erectile dysfunction.
Drug developer Eli Lilly will buy SGX Pharmaceuticals for about $64 million in cash in an effort to expand its drug discovery efforts, the companies said Tuesday.
On another ugly day for the stock markets, beaten down shares of Dow component Merck rallied. The stock started picking up steam after the news broke late this morning that its late-stage experimental migraine headache drug essentially works just as well as an existing drug, but with fewer side effects.
Tree huggers (just a colloquialism, not a dig) will be glad to know that biopharmaceutical companies submit their Food and Drug Administration filings for drug approval electronically these days.
As much as I tried to disconnect during my vacation last week, I couldn't escape the ubiquitous presence of pharmaceuticals in our everyday lives...
Japanese drug maker Daiichi Sankyo will pay up to $4.6 billion for control of India's Ranbaxy Laboratories, the latest in a string of global health deals as firms look to bulk up and diversify to fend off aggressive rivals.
Despite the Dow's slight uptick, inflation and credit concerns continued to weigh heavily on stocks Tuesday.
First, last Friday, Novo Nordisk put out a press release saying preliminary data show its drug works better than Byetta. And then, yesterday an analyst downgraded the stock just ahead of the company's long anticipated release of long-term results on its once-a-week version of Byetta.